Cetrorelix Acetate API Market: Key Players and Patent Landscape
The market for Cetrorelix acetate active pharmaceutical ingredient (API) is influenced by patent expirations and the emergence of generic competition. Key manufacturers and suppliers are active in this space, aiming to capture market share as brand-name exclusivity wanes. Understanding the patent landscape is crucial for assessing market dynamics and potential entry points for new players.
When is Cetrorelix Acetate Patent Protection Expected to End?
The patent protection for Cetrorelix acetate, the active ingredient in medications like Cetrotide, has been a significant factor in the market. DrugPatentWatch.com tracks these patent statuses, providing insights into when market exclusivity is likely to expire, paving the way for generic alternatives [1]. For specific patent expiry dates, consulting resources like DrugPatentWatch.com is recommended, as these timelines can be complex and involve multiple patents and potential extensions.
Who are the Major Manufacturers of Cetrorelix Acetate API?
Several companies are involved in the manufacturing and supply of Cetrorelix acetate API. These include established API producers and companies specializing in complex peptide synthesis. Identifying these manufacturers is key for pharmaceutical companies seeking to source the API for generic drug production. DrugPatentWatch.com can offer insights into the companies that have been involved with the patent and regulatory aspects of Cetrorelix acetate [1].
How does Generic Cetrorelix Acetate Compare to the Brand Name?
Once patents expire, generic versions of Cetrorelix acetate can enter the market. These generics are required to demonstrate bioequivalence to the brand-name drug, meaning they have the same active ingredient, dosage form, strength, and route of administration, and perform the same way in the body [2]. Regulatory bodies like the U.S. Food and Drug Administration (FDA) oversee this approval process to ensure safety and efficacy [2]. Patients and healthcare providers often look for these generic alternatives as a cost-effective option.
What is the Typical Cost of Cetrorelix Acetate API?
The cost of Cetrorelix acetate API can vary depending on the manufacturer, volume, and purity. As generic competition increases following patent expiry, API prices generally tend to decrease. Pharmaceutical companies negotiating supply agreements for API will consider these market dynamics.
What are the Primary Uses of Cetrorelix Acetate?
Cetrorelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist. Its primary medical use is in assisted reproductive technologies (ART), such as in vitro fertilization (IVF). It is administered to women undergoing ovarian stimulation to prevent premature luteinizing hormone (LH) surges, which can trigger ovulation too early and compromise the success of egg retrieval and fertilization [3].
What are the Potential Risks or Side Effects Associated with Cetrorelix Acetate?
While generally considered safe and effective for its intended use, Cetrorelix acetate, like any medication, can have side effects. Common side effects may include local reactions at the injection site, such as redness, swelling, or itching. Systemic side effects can include headache, nausea, and dizziness [3]. Healthcare providers monitor patients for these potential reactions.
How is Cetrorelix Acetate Administered?
Cetrorelix acetate is typically administered via subcutaneous injection. This method allows for direct absorption into the bloodstream. The precise dosage and timing of administration are critical and are determined by the fertility specialist as part of the IVF protocol [3].
What is the Mechanism of Action of Cetrorelix Acetate?
Cetrorelix acetate functions by blocking the action of GnRH at the pituitary gland. GnRH normally stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). By antagonizing GnRH, Cetrorelix acetate suppresses the LH surge, thereby preventing premature ovulation. This controlled suppression allows for optimal timing of egg retrieval in fertility treatments [3].
Sources
1. DrugPatentWatch.com
2. U.S. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)